The Biomarkers Market, size was estimated USD 66.8 billion in 2022 and is expected to reach USD182.6 billion by 2030 at a CAGR of 13.4% during the forecast period of 2023-2030.
A biomarker or biological marker is a measurable indicator of the biological state or condition of an organ or a tissue, or a cell. Biomarkers are widely used in medicine, safety assessment, and drug discovery and development. Biomarkers can be classified into various types according to their functionality, such as diagnostics biomarkers, prognostic biomarkers, predictive biomarker, and others. They play an important role in improving the drug development process as well as in the larger biomedical research enterprise. Based on the biological properties, biomarkers are also categorized as genomics, proteomics, and others. Increase in the diagnostic applications of biomarkers is one of the major factors propelling the growth of the biomarker industry. An increase in the number of research and development activities, funded by biotechnology and pharmaceutical companies coupled with the rising prevalence of cancer are some of the major biomarker market trends boosting the demand and thereby, accelerating the growth of the market.
Increased investments in biomarker research, an increase in the prevalence of cancer, the growing importance of companion diagnostics, and substantial advances as a result of continuing research are all predicted to propel market growth. Research contributes to the creation of efficient treatments for a range of illnesses, including cancer, cardiovascular, immunological, and neurological conditions. It also aids in comprehending how a certain disease might be avoided and first identified. There has been a noticeable rise in both governmental and private investment in the sector. An organ, tissue, or cell's biological status or condition can be determined by a biomarker, also known as a biological marker. In medicine, safety evaluation, and other fields, biomarkers.
DRIVERS
International increase in cancer incidence.
Due to factors including the rising incidence of smoking, bad eating habits, and physical inactivity, among others, the burden of cancer is predicted to increase in the future. Biomarkers can reveal a range of aspects of health or disease. Cancer is a difficult illness with a multi-stage carcinogenesis process that involves several molecular pathway events, making diagnosis, prognosis, and treatment difficult. A single marker is ineffective because cancer is complicated. Additionally, each kind of cancer has a unique molecular profile compared to the others. The identification of novel biomarkers opens up new avenues for the development of treatment approaches intended to correct dysregulation in cancer. As a result, the worldwide market for biomarkers will expand due to the rising incidence of cancer.
RESTRAIN
High startup costs and protracted biomarker development cycles.
OPPORTUNITY
Developing nations.
Diagnostic biomarkers have a lot of room to grow in developing nations like China and India. This is partly attributable to the expanding patient population and resulting rise in illnesses like cancer and cardiovascular disease in these nations. According to research conducted by the American Heart Association (AHA), yearly cardiovascular events in China were predicted to rise by more than 50% between 2010 and 2030, with risk variables staying the same. The Lancet reports that in 2016, cardiovascular illnesses were responsible for 28% of all deaths in India, and that number is expected to rise to 36% by 2030. The need for early illness diagnostic techniques will be driven by the rising occurrence and burden of cardiovascular diseases in emerging nations, which will provide several potential players in the market for biomarker testing.
CHALLENGES
Technical difficulties with the collecting and storage of samples.
Geopolitical conflicts and wars may generally have a wide range of repercussions on a variety of sectors and businesses. Potential fluctuations in the biomarkers market may be influenced by a variety of elements, including changes in government regulations, changes in investment attitude, interruptions in commerce, supply networks, and manufacturing capacity in the afflicted areas, as well as alterations in consumer behaviour in reaction to the crisis to get current knowledge on how the conflict between Russia and Ukraine is affecting the market for biomarkers.
IMPACT OF ONGOING RECESSION
Healthcare Costs People and governments alike frequently cut back on their healthcare spending during economic downturns. Due to patients' desire to conserve money, non-essential medical consultations and tests may be put off, which can have an impact on diagnostic testing, especially biomarker-based examinations. Changing Demand There may be a shift in the demand for healthcare during a recession from certain regions to others. For instance, there may be greater demand for biomarkers used in early illness detection and preventative healthcare since they can aid in the earlier diagnosis of diseases, which may result in lower long-term treatment costs. Consolidation of the Market During economic downturns, smaller businesses may find it difficult to survive, while larger, more established businesses may decide to buy out or combine with other, less powerful firms. The overall competitiveness and innovation in the industry might be impacted by this concentration in the market for biomarkers.
Putting Value-Based Medicine First, Healthcare systems may prioritise value-based treatment and cost-effectiveness during recessions. More focus and acceptance may be given to biomarkers that show definite therapeutic advantages and cost reductions in patient treatment.
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Other Applications
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Other Disease Indications
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
Due to the high illness burden, rising consumer awareness of biomarkers, encouraging government efforts, technical breakthroughs, and improvements in healthcare infrastructure, North America dominated the global business in 2022 with a revenue share of more than 45.0%. A significant element anticipated to fuel the region's growth is the presence of prominent firms in this area and the many organic and inorganic projects they have undertaken.
On the other side, Asia-Pacific is likely to increase at the quickest rate throughout the projected time. Regional expansion is anticipated to be supported by elements including a rise in financing for the discovery of biomarkers, a high cancer prevalence, expanding research activities, and affordable clinical trials in emerging countries. Additionally, it is anticipated that an increase in financing for biotech and pharmaceutical firms, an increase in the number of CROs, and a broadening of the use of biomarkers would support regional market expansion within the anticipated time frame.
The major key players are F. Hoffmann-La Roche Ltd., Abbott, Epigenomics AG, General Electric, Johnson & Johnson Services, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, QIAGEN and others.
F. Hoffmann-La Roche Ltd: In December 2022, The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Elecsys beta-amyloid (1-42) CSF II (Abeta42) and Elecsys phospho-Tau (181P) CSF (pTau181) tests, according to F. Hoffmann-La Roche Ltd. (Switzerland). In persons 55 years of age and older who are being assessed for Alzheimer's disease, the Elecsys AD CSF Abeta42 and pTau181 tests (used as a pTau181/Abeta42 ratio) examine two biomarkers that are hallmarks of Alzheimer's pathology, beta-amyloid and tau proteins.
Enzo Biochem: In September 2022, AMPIVIEW Gene Expression Platform by Enzo Biochem was introduced with products for HPV and SARS-CoV-2 detection.
| Report Attributes | Details |
| Market Size in 2022 | US$ 66.8 Bn |
| Market Size by 2030 | US$ 182.6 Bn |
| CAGR | CAGR of 13.4% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Consumables, Services, Software) • By Type (Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamics Biomarkers, Prognostic Biomarkers) • By Application (Diagnostics, Drug Discovery & Development) • By Disease Indication (Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | F. Hoffmann-La Roche Ltd., Abbott, Epigenomics AG, General Electric, Johnson & Johnson Services, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, QIAGEN |
| Key Drivers | • International increase in cancer incidence. |
| Market Restraints | • High startup costs and protracted biomarker development cycles. |
Ans: Biomarkers Market is anticipated to expand by 66.8% from 2023 to 2030.
Ans: USD 182.6 billion is expected to grow by 2030.
Ans: Biomarkers Market size was valued at USD 66.8 billion in 2022.
Ans: Throughout the forecast period, factors such as the rising frequency of chronic illnesses, technological developments in the methods used to generate diagnoses based on biomarkers, and the rising geriatric population are projected to have a substantial positive impact on the biomarkers market.
Ans: In 2022, cancer had 36.7% of the market share and led the illness sector, thanks to rising demand for quick and precise diagnostic technologies as well as a steep rise in global prevalence.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Biomarkers Market, By Product
8.1 Consumables
8.2 Services
8.3 Software
9. Biomarkers Market, By Type
9.1 Safety Biomarkers
9.2 Efficacy Biomarkers
9.3 Predictive Biomarkers
9.4 Surrogate Biomarkers
9.5 Pharmacodynamics Biomarkers
9.6 Prognostic Biomarkers
9.7 Validation Biomarkers
10. Biomarkers Market, By Application
10.1 Diagnostics
10.2 Drug Discovery & Development
10.3 Personalized Medicine
10.4 Disease Risk Assessment
10.5 Other Applications
11. Biomarkers Market, By Disease Indication
11.1 Cancer
11.2 Infectious Diseases
11.3 Immune Disorders
11.4 Neurological Disorders
11.5 Cardiovascular Disorders
11.6 Other Disease Indications
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Biomarkers Market by Country
12.2.2North America Biomarkers Market By Product
12.2.3 North America Biomarkers Market By Type
12.2.4 North America Biomarkers Market By Application
12.2.5 North America Biomarkers Market by Disease Indication
12.2.6 USA
12.2.6.1 USA Biomarkers Market By Product
12.2.6.2 USA Biomarkers Market By Type
12.2.6.3 USA Biomarkers Market By Application
12.2.6.4 USA Biomarkers Market by Disease Indication
12.2.7 Canada
12.2.7.1 Canada Biomarkers Market By Product
12.2.7.2 Canada Biomarkers Market By Type
12.2.7.3 Canada Biomarkers Market By Application
12.2.7.4 Canada Biomarkers Market by Disease Indication
12.2.8 Mexico
12.2.8.1 Mexico Biomarkers Market By Product
12.2.8.2 Mexico Biomarkers Market By Type
12.2.8.3 Mexico Biomarkers Market By Application
12.2.8.4 Mexico Biomarkers Market by Disease Indication
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Biomarkers Market by Country
12.3.1.2 Eastern Europe Biomarkers Market By Product
12.3.1.3 Eastern Europe Biomarkers Market By Type
12.3.1.4 Eastern Europe Biomarkers Market By Application
12.3.1.5 Eastern Europe Biomarkers Market by Disease Indication
12.3.1.6 Poland
12.3.1.6.1 Poland Biomarkers Market By Product
12.3.1.6.2 Poland Biomarkers Market By Type
12.3.1.6.3 Poland Biomarkers Market By Application
12.3.1.6.4 Poland Biomarkers Market by Disease Indication
12.3.1.7 Romania
12.3.1.7.1 Romania Biomarkers Market By Product
12.3.1.7.2 Romania Biomarkers Market By Type
12.3.1.7.3 Romania Biomarkers Market By Application
12.3.1.7.4 Romania Biomarkers Market by Disease Indication
12.3.1.8 Hungary
12.3.1.8.1 Hungary Biomarkers Market By Product
12.3.1.8.2 Hungary Biomarkers Market By Type
12.3.1.8.3 Hungary Biomarkers Market By Application
12.3.1.8.4 Hungary Biomarkers Market by Disease Indication
12.3.1.9 Turkey
12.3.1.9.1 Turkey Biomarkers Market By Product
12.3.1.9.2 Turkey Biomarkers Market By Type
12.3.1.9.3 Turkey Biomarkers Market By Application
12.3.1.9.4 Turkey Biomarkers Market by Disease Indication
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Biomarkers Market By Product
12.3.1.10.2 Rest of Eastern Europe Biomarkers Market By Type
12.3.1.10.3 Rest of Eastern Europe Biomarkers Market By Application
12.3.1.10.4 Rest of Eastern Europe Biomarkers Market by Disease Indication
12.3.2 Western Europe
12.3.2.1 Western Europe Biomarkers Market by Country
12.3.2.2 Western Europe Biomarkers Market By Product
12.3.2.3 Western Europe Biomarkers Market By Type
12.3.2.4 Western Europe Biomarkers Market By Application
12.3.2.5 Western Europe Biomarkers Market by Disease Indication
12.3.2.6 Germany
12.3.2.6.1 Germany Biomarkers Market By Product
12.3.2.6.2 Germany Biomarkers Market By Type
12.3.2.6.3 Germany Biomarkers Market By Application
12.3.2.6.4 Germany Biomarkers Market by Disease Indication
12.3.2.7 France
12.3.2.7.1 France Biomarkers Market By Product
12.3.2.7.2 France Biomarkers Market By Type
12.3.2.7.3 France Biomarkers Market By Application
12.3.2.7.4 France Biomarkers Market by Disease Indication
12.3.2.8 UK
12.3.2.8.1 UK Biomarkers Market By Product
12.3.2.8.2 UK Biomarkers Market By Type
12.3.2.8.3 UK Biomarkers Market By Application
12.3.2.8.4 UK Biomarkers Market by Disease Indication
12.3.2.9 Italy
12.3.2.9.1 Italy Biomarkers Market By Product
12.3.2.9.2 Italy Biomarkers Market By Type
12.3.2.9.3 Italy Biomarkers Market By Application
12.3.2.9.4 Italy Biomarkers Market by Disease Indication
12.3.2.10 Spain
12.3.2.10.1 Spain Biomarkers Market By Product
12.3.2.10.2 Spain Biomarkers Market By Type
12.3.2.10.3 Spain Biomarkers Market By Application
12.3.2.10.4 Spain Biomarkers Market by Disease Indication
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Biomarkers Market By Product
12.3.2.11.2 Netherlands Biomarkers Market By Type
12.3.2.11.3 Netherlands Biomarkers Market By Application
12.3.2.11.4 Netherlands Biomarkers Market by Disease Indication
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Biomarkers Market By Product
12.3.2.12.2 Switzerland Biomarkers Market By Type
12.3.2.12.3 Switzerland Biomarkers Market By Application
12.3.2.12.4 Switzerland Biomarkers Market by Disease Indication
12.3.2.13 Austria
12.3.2.13.1 Austria Biomarkers Market By Product
12.3.2.13.2 Austria Biomarkers Market By Type
12.3.2.13.3 Austria Biomarkers Market By Application
12.3.2.13.4 Austria Biomarkers Market by Disease Indication
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Biomarkers Market By Product
12.3.2.14.2 Rest of Western Europe Biomarkers Market By Type
12.3.2.14.3 Rest of Western Europe Biomarkers Market By Application
12.3.2.14.4 Rest of Western Europe Biomarkers Market by Disease Indication
12.4 Asia-Pacific
12.4.1 Asia Pacific Biomarkers Market by Country
12.4.2 Asia Pacific Biomarkers Market By Product
12.4.3 Asia Pacific Biomarkers Market By Type
12.4.4 Asia Pacific Biomarkers Market By Application
12.4.5 Asia Pacific Biomarkers Market by Disease Indication
12.4.6 China
12.4.6.1 China Biomarkers Market By Product
12.4.6.2 China Biomarkers Market By Type
12.4.6.3 China Biomarkers Market By Application
12.4.6.4 China Biomarkers Market by Disease Indication
12.4.7 India
12.4.7.1 India Biomarkers Market By Product
12.4.7.2 India Biomarkers Market By Type
12.4.7.3 India Biomarkers Market By Application
12.4.7.4 India Biomarkers Market by Disease Indication
12.4.8 Japan
12.4.8.1 Japan Biomarkers Market By Product
12.4.8.2 Japan Biomarkers Market By Type
12.4.8.3 Japan Biomarkers Market By Application
12.4.8.4 Japan Biomarkers Market by Disease Indication
12.4.9 South Korea
12.4.9.1 South Korea Biomarkers Market By Product
12.4.9.2 South Korea Biomarkers Market By Type
12.4.9.3 South Korea Biomarkers Market By Application
12.4.9.4 South Korea Biomarkers Market by Disease Indication
12.4.10 Vietnam
12.4.10.1 Vietnam Biomarkers Market By Product
12.4.10.2 Vietnam Biomarkers Market By Type
12.4.10.3 Vietnam Biomarkers Market By Application
12.4.10.4 Vietnam Biomarkers Market by Disease Indication
12.4.11 Singapore
12.4.11.1 Singapore Biomarkers Market By Product
12.4.11.2 Singapore Biomarkers Market By Type
12.4.11.3 Singapore Biomarkers Market By Application
12.4.11.4 Singapore Biomarkers Market by Disease Indication
12.4.12 Australia
12.4.12.1 Australia Biomarkers Market By Product
12.4.12.2 Australia Biomarkers Market By Type
12.4.12.3 Australia Biomarkers Market By Application
12.4.12.4 Australia Biomarkers Market by Disease Indication
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Biomarkers Market By Product
12.4.13.2 Rest of Asia-Pacific Biomarkers Market By Type
12.4.13.3 Rest of Asia-Pacific Biomarkers Market By Application
12.4.13.4 Rest of Asia-Pacific Biomarkers Market by Disease Indication
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Biomarkers Market by country
12.5.1.2 Middle East Biomarkers Market By Product
12.5.1.3 Middle East Biomarkers Market By Type
12.5.1.4 Middle East Biomarkers Market By Application
12.5.1.5 Middle East Biomarkers Market by Disease Indication
12.5.1.6 UAE
12.5.1.6.1 UAE Biomarkers Market By Product
12.5.1.6.2 UAE Biomarkers Market By Type
12.5.1.6.3 UAE Biomarkers Market By Application
12.5.1.6.4 UAE Biomarkers Market by Disease Indication
12.5.1.7 Egypt
12.5.1.7.1 Egypt Biomarkers Market By Product
12.5.1.7.2 Egypt Biomarkers Market By Type
12.5.1.7.3 Egypt Biomarkers Market By Application
12.5.1.7.4 Egypt Biomarkers Market by Disease Indication
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Biomarkers Market By Product
12.5.1.8.2 Saudi Arabia Biomarkers Market By Type
12.5.1.8.3 Saudi Arabia Biomarkers Market By Application
12.5.1.8.4 Saudi Arabia Biomarkers Market by Disease Indication
12.5.1.9 Qatar
12.5.1.9.1 Qatar Biomarkers Market By Product
12.5.1.9.2 Qatar Biomarkers Market By Type
12.5.1.9.3 Qatar Biomarkers Market By Application
12.5.1.9.4 Qatar Biomarkers Market by Disease Indication
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Biomarkers Market By Product
12.5.1.10.2 Rest of Middle East Biomarkers Market By Type
12.5.1.10.3 Rest of Middle East Biomarkers Market By Application
12.5.1.10.4 Rest of Middle East Biomarkers Market by Disease Indication
12.5.2. Africa
12.5.2.1 Africa Biomarkers Market by country
12.5.2.2 Africa Biomarkers Market By Product
12.5.2.3 Africa Biomarkers Market By Type
12.5.2.4 Africa Biomarkers Market By Application
12.5.2.5 Africa Biomarkers Market by Disease Indication
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Biomarkers Market By Product
12.5.2.6.2 Nigeria Biomarkers Market By Type
12.5.2.6.3 Nigeria Biomarkers Market By Application
12.5.2.6.4 Nigeria Biomarkers Market by Disease Indication
12.5.2.7 South Africa
12.5.2.7.1 South Africa Biomarkers Market By Product
12.5.2.7.2 South Africa Biomarkers Market By Type
12.5.2.7.3 South Africa Biomarkers Market By Application
12.5.2.7.4 South Africa Biomarkers Market by Disease Indication
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Biomarkers Market By Product
12.5.2.8.2 Rest of Africa Biomarkers Market By Type
12.5.2.8.3 Rest of Africa Biomarkers Market By Application
12.5.2.8.4 Rest of Africa Biomarkers Market by Disease Indication
12.6. Latin America
12.6.1 Latin America Biomarkers Market by country
12.6.2 Latin America Biomarkers Market By Product
12.6.3 Latin America Biomarkers Market By Type
12.6.4 Latin America Biomarkers Market By Application
12.6.5 Latin America Biomarkers Market by Disease Indication
12.6.6 Brazil
12.6.6.1 Brazil Biomarkers Market By Product
12.6.6.2 Brazil Biomarkers Market By Type
12.6.6.3 Brazil Biomarkers Market By Application
12.6.6.4 Brazil Biomarkers Market by Disease Indication
12.6.7 Argentina
12.6.7.1 Argentina Biomarkers Market By Product
12.6.7.2 Argentina Biomarkers Market By Type
12.6.7.3 Argentina Biomarkers Market By Application
12.6.7.4 Argentina Biomarkers Market by Disease Indication
12.6.8 Colombia
12.6.8.1 Colombia Biomarkers Market By Product
12.6.8.2 Colombia Biomarkers Market By Type
12.6.8.3 Colombia Biomarkers Market By Application
12.6.8.4 Colombia Biomarkers Market by Disease Indication
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Biomarkers Market By Product
12.6.9.2 Rest of Latin America Biomarkers Market By Type
12.6.9.3 Rest of Latin America Biomarkers Market By Application
12.6.9.4 Rest of Latin America Biomarkers Market by Disease Indication
13 Company Profile
13.1 F. Hoffmann-La Roche Ltd.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Abbott, Epigenomics AG.
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 General Electric.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Johnson & Johnson Services, Inc.
13.4 Company Overview
13.4.2 Financials
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Thermo Fisher Scientific Inc.
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Bio-Rad Laboratories, Inc.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Siemens Healthcare GmbH.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 QIAGEN.
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 AVI Healthcare Pvt. Ltd.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Epigenomics AG.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Cell Separation Market size was estimated USD 9.06 billion in 2023 and is expected to reach USD 12.68 billion by 2031 at a CAGR of 9.95% during the forecast period of 2024-2031.
The Vitrectomy Devices Market Size was valued at USD 1.24 billion in 2023, and is expected to reach USD 2.05 billion by 2031, and grow at a CAGR of 6.48% over the forecast period 2024-2031.
The Menstrual Cup Market Size was valued at USD 785.13 million in 2022, and is expected to reach USD 1204.9 million by 2030 and grow at a CAGR of 5.5% over the forecast period 2023-2030.
The Surgical Sutures Market size was USD 3.53 billion in 2022 and is expected to Reach USD 5.54 billion by 2030 with a CAGR of 5.8% over the forecast period of 2023-2030.
The Human Insulin Market size was valued at USD 19.21 billion in 2023 and is expected to reach USD 24.71 billion by 2031 and grow at a CAGR of 3.2% over the forecast period of 2024-2031.
The Immunology Market is estimated to be valued at US$ 91,851 Million in 2022 and is expected to reach US$ 156,378.3 million by 2030, at a CAGR of 9% during the forecast period (2023–2030).
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
